Back to search

Article

Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease

2022-11-15

Abstract excerpt

<h4>Background: </h4> & Aims Though obeticholic acid (OCA) is a promising drug for non-alcoholic fatty liver disease (NAFLD), the response rate of OCA is limited. This study aimed to develop a biomarker to optimize OCA treatment for NAFLD. <h4>Methods: </h4> C57BL/6N mice males were fed on a western diet for 24 weeks. Pre-study liver biopsy performed at 12 weeks, and stratified according to disease severity. Next...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2401d75f-7eac-551b-b2f6-2e6fc58f77df
DOI
10.21203/rs.3.rs-2257825/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver diseaseDOI 10.21203/rs.3.rs-2257825/v1
Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver DiseaseSemantic proximity
Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential for applications in human health and diseaseSemantic proximity
Bardoxolone methyl improves non-alcoholic steatohepatitis through inhibition of macrophage infiltration.Semantic proximity
[Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016].Semantic proximity
NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment OptionsSemantic proximity
Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLDSemantic proximity
Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression.Semantic proximity
Advancements in Understanding and Treating NAFLD: A Comprehensive Review of Metabolic-Associated Fatty Liver Disease and Emerging TherapiesSemantic proximity
Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLDSemantic proximity
Modulation of hepatic mRNA-miRNA panel linked to NAFLD/NASH Hippo signaling and gut microbiota after administration of kefir in Non-Alcoholic Steatohepatitis Rat ModelSemantic proximity
Multi-omics analysis reveals gut microbiota remodeling and lipid metabolism regulation during the treatment of nonalcoholic fatty liver disease with Yindan Pinggan capsuleSemantic proximity
A metabolomics approach to the validation of predictive metabolites and phenotypic expression in non-alcoholic fatty liver disease.Semantic proximity
Select a neighboring publication to make it the new centre.